Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olsalazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.72 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.72 |
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | BLVRB | P30043 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.85 |
| ▸ | THRB | P10828 | 2/20 | 0.85 |
| ▸ | RECQL | P46063 | 2/20 | 0.85 |
| ▸ | APP | P05067 | 1/20 | 0.85 |
| ▸ | BLM | P54132 | 1/20 | 0.85 |
| ▸ | PHLPP2 | Q6ZVD8 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olsalazine SCHEMBL29378994 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL2628413 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL29861404 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL25119 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL25118 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL5922630 | 0.98 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL19693100 | 0.98 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL2228872 | 0.98 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL28138401 | 0.98 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL29769 | 0.98 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114369661-B | Marker for breast cancer screening, probe composition and application thereof | 博尔诚（北京）科技有限公司 | 2024-09-20 | — | — | CN | claimed |
| EP-4326887-A1 | BIRDS FOR PRODUCING FEMALE HATCHLING AND METHODS OF PRODUCING SAME | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University (IL) | 2024-02-28 | — | — | EP | claimed |
| WO-2022232614-A2 | COMPOSITIONS AND METHODS FOR TREATING INDIVIDUALS WHO HAVE ONCOGENE-NEGATIVE CANCER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-11-03 | — | — | WO | claimed |
| WO-2022224244-A1 | BIRDS FOR PRODUCING FEMALE HATCHLING AND METHODS OF PRODUCING SAME | B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2022-10-27 | — | — | WO | claimed |
| CN-114729399-A | Detection of ovarian cancer | 梅约医学教育与研究基金会 | 2022-07-08 | — | — | CN | claimed |
| CN-114144180-A | Method for treating bile duct cancer | QED医药股份有限公司 | 2022-03-04 | — | — | CN | claimed |
| US-20260144862-A1 | MATERIALS AND METHODS TO TREAT EPSTEIN-BARR VIRUS (EBV) AND EBV-INDUCED DISEASES | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2026-05-28 | — | — | US | disclosed |
| CN-122012991-A | High-wear-resistance corrosion-resistant Zn-Mn-Cr-Mg zinc alloy and preparation method and application thereof | 北京科技大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20260108606-A1 | TREATMENT OF AUTOIMMUNE DISEASES HAVING A PATHOGENIC T CELL STATE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| CN-121818680-A | Use of alpha-glucosidase inhibitor in preparation of medicines for treating gastric cancer | 福建医科大学附属协和医院 | 2026-04-10 | — | — | CN | disclosed |
| US-12594285-B2 | Compositions and methods for protecting against airborne pathogens and irritants | APPLIED BIOLOGICAL LABORATORIES, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260077033-A1 | METHODS FOR TREATING OR PREVENTING RESPIRATORY DISEASES IN CATTLE USING POLYMERS AND POLYPLEXES FOR mRNA DELIVERY AND mRNA THERAPY | MISSISSIPPI STATE UNIVERSITY OFFICE OF TECHNOLOGY MANAGEMENT (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4692146-A1 | LEVELING AGENT, RESIST COMPOSITION, AND POLARIZING PLATE | DIC Corporation (JP) | 2026-02-11 | — | — | EP | disclosed |
| CN-109814335-B | Colored photosensitive resin composition, color filter and image display device | 东友精细化工有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-110221521-B | Colored photosensitive resin composition, color filter and display device | 东友精细化工有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-107918246-B | Colored curable resin composition | 住友化学株式会社 | 2022-02-25 | — | — | CN | disclosed |
| CN-114080567-A | Composition containing colorant | 住友化学株式会社 | 2022-02-22 | — | — | CN | disclosed |
| CN-108459466-B | Colored photosensitive resin composition for red pixel, color filter and application thereof | 东友精细化工有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-114072495-A | Modified immune cells with enhanced antitumor activity and immunosuppressive resistance | 比姆医疗股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20220047614-A1 | COMPOSITIONS AND METHODS FOR PROTECTING AGAINST AIRBORNE PATHOGENS AND IRRITANTS | TRANSMINEO LLC | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144862-A1 | MATERIALS AND METHODS TO TREAT EPSTEIN-BARR VIRUS (EBV) AND EBV-INDUCED DISEASES | MALT1, BCL3, BCL6 | PTGS2 1653/4885PTGS1 1158/4885ALOX5 736/4885 |
| US-20260108606-A1 | TREATMENT OF AUTOIMMUNE DISEASES HAVING A PATHOGENIC T CELL STATE | IL17A, CD4, PMP22 | PTGS2 1413/4885PTGS1 1293/4885ALOX5 2307/4885 |
| US-20260077033-A1 | METHODS FOR TREATING OR PREVENTING RESPIRATORY DISEASES IN CATTLE USING POLYMERS AND POLYPLEXES FOR mRNA DELIVERY AND mRNA THERAPY | MED25, CARD19, HM13 | PTGS2 1812/4885PTGS1 1763/4885ALOX5 615/4885 |
| US-12594285-B2 | Compositions and methods for protecting against airborne pathogens and irritants | SIGLEC7, ICAM1, NEU1 | PTGS2 4084/4885PTGS1 2831/4885ALOX5 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.